DOI: https://doi.org/10.15587/2519-4852.2018.141411

Research of 1,3-oxazole-4-il-phosphonic acid derivative on the content of fatty acids of lipids in rats with arterial hypertension

Kateryna Matskevych

Abstract


The number of patients with arterial hypertension (AH) continues to increase. Significant negative effects of arterial hypertension are structural, metabolic and functional disorders in the tissues of the myocardium, vessels and other organs, in particular, changes in the content of fatty acids (FA) and their correlation. The purpose of the study is to investigate the change in fatty acid composition of lipids in blood serum and tissues of rats with arterial hypertension under the influence of a new original compound, 1,3-oxazole-4-yl-phosphonic acid derivative (abbreviated name - oxazole derivative).

Materials and methods. The studies were conducted on white, sexually mature rats. Arterial hypertension was modeled by salt load - salt drink (1 % solution of sodium chloride) with free access to it for 21 days. Animals from the 14th day received oxazole derivative at a dose of 25 mg / kg intraperitoneally, once daily, for 7 days. The content of fatty acids of centrifuged blood serum and homogenized in 0.9 % saline NaCl tissue was determined by gas chromatographic analysis.

Results and discussion. The administration of oxazole derivative in the background of increased blood pressure in rats did not significantly affect the amount of SFA and USFA in serum in contrast to the group of rats with hypertension due to the tendency to restore the stearic acid content, but the changed content of linoleic and arachidonic acids practically did not differ from the values in the blank group. There was a restoration of the content of palmitic, stearic, linoleic and arachidonic acids in aorta. In heart, the change in the content of linoleic and arachidonic acids in the reverse direction compared with the blank group was established.

Conclusions. The administration of 25 mg/kg (ED50) of oxazole derivative intravenous intraperitoneally once daily for 7 days with simultaneous simulation of arterial hypertension by salt load did not cause any adverse changes and led to the restoration of lipid parameters of SFA, USFA and PUFA


Keywords


arterial hypertension; fatty acids; 1;3-oxazole-4-yl-phosphonic acid derivative; oxazole derivative; rats

Full Text:

PDF

References


World Health Organization. Global status report on noncommunicable diseases 2010 (2010). Geneva: WHO.

Klinicheskie ispytaniya lekarstvennyh sredstv i farmakonadzor v Ukraine (2001). Mater. nauchno-prak. seminara 1-2 iyunya 2001 g. Kyiv: Aviacenna, 128.

World Health Organization. A global brief on hypertension 2013 (2013). Geneva: WHO.

Unification of the protocol of extrinsic medical assistance. Hypertonic crisis. Available at: http://moz.gov.ua/nakazi-moz

Arutyunov, G. P., Nedogoda, S. V., Gilyarevskiy, S. R., Baranova, E. I. et. al. (2015). Slozhnye voprosy lecheniya arterial'noy gipertenzii: vliyanie povyshennoy chastoty serdechnyh sokrashcheniy i soputstvuyushchih zabolevaniy na vybor antigipertenzivnoy terapii v praktike kardiologa i terapevta [Complex questions of treatment of arterial hypertension: the effect of increased heart rate and concomitant diseases on the choice of antihypertensive therapy in the practice of a cardiologist and therapist]. Ration Pharmacother Cardiol, 11 (1), 63–67.

Popov, V. V., Bulanov, N. A., Ivanov, G. G. (2012). Current target of antihypertensive therapy. Data from clinical trials. Part 1. Rational Pharmacotherapy in Cardiology, 8 (1), 88–94. doi: https://doi.org/10.20996/1819-6446-2012-8-1-88-94

Zahorodniy, M. I., Briuzghina, T. S., Svintsytskyi, A. S. (2008). Zminy zhyrnokyslotnoho spektru lipidiv u shchuriv zi spontannoiu arterialnoiu hipertenzieiu [Changes in the fatty acid spectrum of lipids in spontaneous arterial hypertension rats]. Sertse i sudyny, 3, 80–84.

Talati, M., Hemnes, A. (2015). Fatty Acid Metabolism in Pulmonary Arterial Hypertension: Role in Right Ventricular Dysfunction and Hypertrophy. Pulmonary Circulation, 5 (2), 269–278. doi: https://doi.org/10.1086/681227

Dovhan, R. S. (2014). Zminy vmistu zhyrnykh kyslot v miokardi ta plazmi krovi shchuriv z arterialnoiu hipertenziieiu pry zastosuvanni antyhipertenzyvnykh zasobiv [Changes in the content of fatty acids in the myocardium and blood plasma of rats with arterial hypertension in the use of antihypertensive drugs]. Visnyk problem biolohiyi i medytsyny, 2 (3), 130–134.

Nizhenkovska, I. V., Sedko, V. K., Golovchenko, O. V., Golovchenko, O. I. (2018). The study of acute toxicity of 1,3-oxazole-4-il-phosphonic acid derivative in intraperitoneal administration. News of Pharmacy, 1 (93), 43–48. doi: https://doi.org/10.24959/nphj.18.2186

Nizhenkovskaya, I. V., Zaychenko, A. V., Sed'ko, E. V., Golovchenko, A. V. (2018). Issledovanie vliyaniya proizvodnogo 1,3-oksazol-4-il-fosfonovoy kisloty na arterial'noe davlenie i serdechnyy ritm u krolikov [Investigation of the effect of the 1,3-oxazole-4-yl-phosphonic acid derivative on blood pressure and heart rate in rabbits]. Recept, 21 (1), 75–83.

European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes. Available at: http://conventions.coe.int/treaty/en/treaties/html/123.htm

Pro zakhyst tvaryn vid zhorstokoho povodzhennia. Zakon vid 21.02.2006 No. 3447-IV. Verkhovna Rada Ukrainy. Available at: http://zakon4.rada.gov.ua/laws/show/3447-15

Badyal, D. K., Lata, H., Dadhich, A. P. (2003). Animal models of hypertension and effect of drugs. Indian J. Pharmacol., 35 (6), 349–362.

Puzyrenko, A. M., Chekman, I. S., Briuzghina, T. S., Horchakova, N. O. (2013). Vplyv antyhipertenzyvnykh ta metabolitropnykh preparativ na zhyrnokyslotnyi sklad lipidiv kardiomiotsytiv u shchuriv zi spontannoiu arterialnoiu hipertenzieiu [Influence of antihypertensive and metabolic drugs on fatty acids content of lipids in cardiomyocytes of rats with spontaneous hypertension]. Ukrainskyi biokhimichnyi zhurnal, 85 (4), 67–74.

Dovhan, R. S., Zahorodnyi, M. I., Briuzghna, T. S., Horchakova, N. O. (2016). Vyvchennia diyi metabolitnykh preparativ na zhyrnokyslotnyi sklad lipidiv tkanyn shchuriv zi spontannoiu arterialnoiu hipertenzieiu [Investigations of metabolite drugs action on fatty acid composition of lipids in tissues of rats with spontaneous hypertension]. Visnyk VDNZU «Ukrainska medychna stomatolohichna akademiya», 16 (1), 202–205.

Nizhenkovska, I. V., Narokha, V. P., Kuznetsova, O. V., Briuzghina, T. S., Seifullina, I. Y., Martsynko, O. E., Chebanenko, O. A. (2015). Vplyv nikotynovoi kysloty ta kompleksu hermaniu z nikotynovoiu kyslotoiu (MIHU­1) na zhyrnokyslotnyi sklad lipidiv kardiomiotsytiv i hepatotsytiv shchuriv z eksperymentalnoiu khronichnoiu sertsevoiu nedostatnistiu [Effects of nicotinic acid and complex of germanium with nicotinic acid (MIGU-1) on lipid fatty acid composition of cardiomyocytes and hepatocytes in rats with experimental chronic heart failure]. Farmakolohiya ta likarska toksykolohiya, 1, 68–75.

Cohen, M., Sztokalo, J., Hinsch, E. (1973). The antihypertensive action of arachidonic acid in the spontaneous hypertensive rat and its antagonism by anti-inflammatory agents. Life Sciences, 13 (4), 317–325. doi: https://doi.org/10.1016/0024-3205(73)90223-3

Renke, M., Knap, N., Tylicki, L., Rutkowski, P., Lizakowski, S., Woźniak, M., Rutkowski, B. (2013). Isoprostanes – important marker of the oxidative stress estimation in patients with chronic kidney disease. Pol. Merkur. Lekarski, 34 (199), 14–17.


GOST Style Citations


World Health Organization. Global status report on noncommunicable diseases 2010. Geneva: WHO, 2010.

Klinicheskie ispytaniya lekarstvennyh sredstv i farmakonadzor v Ukraine // Mater. nauchno-prak. seminara 1-2 iyunya 2001 g. Kyiv: Aviacenna, 2001. 128 p.

World Health Organization. A global brief on hypertension 2013. Geneva: WHO, 2013.

Unification of the protocol of extrinsic medical assistance. Hypertonic crisis. URL: http://moz.gov.ua/nakazi-moz

Slozhnye voprosy lecheniya arterial'noy gipertenzii: vliyanie povyshennoy chastoty serdechnyh sokrashcheniy i soputstvuyushchih zabolevaniy na vybor antigipertenzivnoy terapii v praktike kardiologa i terapevta [Complex questions of treatment of arterial hypertension: the effect of increased heart rate and concomitant diseases on the choice of antihypertensive therapy in the practice of a cardiologist and therapist] / Arutyunov G. P. et. al. // Ration Pharmacother Cardiol. 2015. Vol. 11, Issue 1. P. 63–67.

Popov V. V., Bulanov N. A., Ivanov G. G. Current target of antihypertensive therapy. Data from clinical trials. Part 1 // Rational Pharmacotherapy in Cardiology. 2012. Vol. 8, Issue 1. P. 88–94. doi: https://doi.org/10.20996/1819-6446-2012-8-1-88-94 

Zahorodniy M. I., Briuzghina T. S., Svintsytskyi A. S. Zminy zhyrnokyslotnoho spektru lipidiv u shchuriv zi spontannoiu arterialnoiu hipertenzieiu [Changes in the fatty acid spectrum of lipids in spontaneous arterial hypertension rats] // Sertse i sudyny. 2008. Issue 3. P. 80–84.

Talati M., Hemnes A. Fatty Acid Metabolism in Pulmonary Arterial Hypertension: Role in Right Ventricular Dysfunction and Hypertrophy // Pulmonary Circulation. 2015. Vol. 5, Issue 2. P. 269–278. doi: https://doi.org/10.1086/681227 

Dovhan R. S. Zminy vmistu zhyrnykh kyslot v miokardi ta plazmi krovi shchuriv z arterialnoiu hipertenziieiu pry zastosuvanni antyhipertenzyvnykh zasobiv [Changes in the content of fatty acids in the myocardium and blood plasma of rats with arterial hypertension in the use of antihypertensive drugs] // Visnyk problem biolohiyi i medytsyny. 2014. Vol. 2, Issue 3. P. 130–134.

The study of acute toxicity of 1,3-oxazole-4-il-phosphonic acid derivative in intraperitoneal administration / Nizhenkovska I. V. et. al. // News of Pharmacy. 2018. Issue 1 (93). P. 43–48. doi: https://doi.org/10.24959/nphj.18.2186 

Issledovanie vliyaniya proizvodnogo 1,3-oksazol-4-il-fosfonovoy kisloty na arterial'noe davlenie i serdechnyy ritm u krolikov [Investigation of the effect of the 1,3-oxazole-4-yl-phosphonic acid derivative on blood pressure and heart rate in rabbits] / Nizhenkovskaya I. V. et. al. // Recept. 2018. Vol. 21, Issue 1. P. 75–83.

European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes. URL: http://conventions.coe.int/treaty/en/treaties/html/123.htm

Pro zakhyst tvaryn vid zhorstokoho povodzhennia. Zakon vid 21.02.2006 No. 3447-IV. Verkhovna Rada Ukrainy. URL: http://zakon4.rada.gov.ua/laws/show/3447-15

Badyal D. K., Lata H., Dadhich A. P. Animal models of hypertension and effect of drugs // Indian J. Pharmacol. 2003. Vol. 35, Issue 6. P. 349–362.

Vplyv antyhipertenzyvnykh ta metabolitropnykh preparativ na zhyrnokyslotnyi sklad lipidiv kardiomiotsytiv u shchuriv zi spontannoiu arterialnoiu hipertenzieiu [Influence of antihypertensive and metabolic drugs on fatty acids content of lipids in cardiomyocytes of rats with spontaneous hypertension] / Puzyrenko A. M. et. al. // Ukrainskyi biokhimichnyi zhurnal. 2013. Vol. 85, Issue 4. P. 67–74.

Vyvchennia diyi metabolitnykh preparativ na zhyrnokyslotnyi sklad lipidiv tkanyn shchuriv zi spontannoiu arterialnoiu hipertenzieiu [Investigations of metabolite drugs action on fatty acid composition of lipids in tissues of rats with spontaneous hypertension] / Dovhan R. S. et. al. // Visnyk VDNZU «Ukrainska medychna stomatolohichna akademiya». 2016. Vol. 16, Issue 1. P. 202–205.

Vplyv nikotynovoi kysloty ta kompleksu hermaniu z nikotynovoiu kyslotoiu (MIHU­1) na zhyrnokyslotnyi sklad lipidiv kardiomiotsytiv i hepatotsytiv shchuriv z eksperymentalnoiu khronichnoiu sertsevoiu nedostatnistiu [Effects of nicotinic acid and complex of germanium with nicotinic acid (MIGU-1) on lipid fatty acid composition of cardiomyocytes and hepatocytes in rats with experimental chronic heart failure] / Nizhenkovska I. V. et. al. // Farmakolohiya ta likarska toksykolohiya. 2015. Issue 1. P. 68–75.

Cohen M., Sztokalo J., Hinsch E. The antihypertensive action of arachidonic acid in the spontaneous hypertensive rat and its antagonism by anti-inflammatory agents // Life Sciences. 1973. Vol. 13, Issue 4. P. 317–325. doi: https://doi.org/10.1016/0024-3205(73)90223-3 

Isoprostanes – important marker of the oxidative stress estimation in patients with chronic kidney disease / Renke M. et. al. // Pol. Merkur. Lekarski. 2013. Vol. 34, Issue 199. P. 14–17.







Copyright (c) 2018 Kateryna Matskevych

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2519-4852 (Online), ISSN 2519-4844 (Print)